New research confirms racial disparities in survival outcomes and representation in clinical trials among Black and White women with a common subtype of endometrial cancer.
Updated data from several clinical trials in both endometrial and cervical cancer could signal the emergence of multiple effective treatment options coming down the pike.
David M. O’Malley, MD, discusses cervical cancer epidemiology, risk factors, and diagnosis, highlighting the importance of HPV vaccinations, regular PAP smears, and the use of various biomarkers for treatment decision making.
Although there are no FDA-approved treatments specifically indicated for low-grade serous ovarian cancer, therapeutic options for these patients are rapidly expanding, with promising new approaches progressing through clinical development.